Submucous Tissue Retention for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nucleic acid pharmaceutical agents face challenges with rapid degradation and the induction of adverse immune responses when administered with carriers, limiting their retention and effectiveness in target tissues.
Innovation Solution
Administering nucleic acids directly into submucous tissues, where they are retained and function as a natural delivery system, avoiding the need for carriers and enhancing localized retention and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acids are administered using carriers (viral vectors, liposomes, atelocollagen), then delivery efficiency is improved, but adverse immune responses are induced and retention duration is limited to about one week
Solution Approach 1:
The invention extracts and eliminates the carrier component from the nucleic acid delivery system. By administering naked nucleic acids directly into the submucous tissue without viral vectors, liposomes, or atelocollagen carriers, the patent removes the source of adverse immune responses while maintaining delivery efficiency through direct tissue injection
Solution Approach 2:
The submucous tissue itself serves as the delivery system, utilizing its natural physiological properties to retain and release nucleic acids. The tissue's inherent structure and composition provide the retention mechanism, eliminating the need for external carriers and their associated immune risks
2Ease of operation
If nucleic acids are administered using carriers, then delivery is facilitated, but retention duration is limited to about one week
Solution Approach 1:
The invention changes the retention mechanism from carrier-dependent to tissue-dependent parameters. By utilizing the submucous tissue's natural composition (extracellular matrix, cellular structure, and physiological environment), the system achieves extended retention beyond one week without relying on carrier materials
3Device complexity
If carriers are used for nucleic acid administration, then delivery system complexity is reduced, but safety is compromised due to immune reactions
Solution Approach 1:
The patent removes the carrier element entirely from the delivery system, administering nucleic acids in their naked form. This simplification eliminates the complexity of carrier design and composition while simultaneously removing the source of immune reactions, achieving both simplicity and safety
Data Source
AI summary
The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.